Shilpa Biologicals partners with mAbTree Biologics for novel immuno-oncology asset
Shilpa to undertake both development and commercial supply for mAbTree’s novel checkpoint inhibitor
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
immuno-oncology
Cancer therapeutics present strongest innovation pipeline in next five years, says GlobalData
In GlobalData’s recent survey, 41 per cent of surveyed industry professionals indicated that immuno-oncology presents the…
Immuno-oncology agents continue to transform cancer treatment landscape: GlobalData
GlobalData’s latest report, "Thematic Research: Immuno-Oncology” explores the IO pipeline and identifies over 700 novel agents…
Advanced antibodies will revolutionise the future of Immuno-Oncology (IO)
Hannah Hall, Consultant, Citeline, explains how the field of immuno-oncology is poised to transform with the help of advanced…
Immuno-oncology to be a dominant class of drugs for hepatocellular carcinoma by 2029: GlobalData
Class-wide sales of IO are expected to grow to 72.2 per cent of the market, contributing $3.8 billion to global sales in 2029 and…
Doctors keen to adopt novel biomarkers for immuno-oncology regimens: GlobalData
The most promising or anticipated biomarker among high-prescribing physicians in the seven major markets was identified to be…
Zydus Cadila inks licensing pact with XOMA Corp
To develop cancer treatment molecule
Zydus Cadila has inked a licensing agreement with Nasdaq listed XOMA Corporation to…
Sanofi teams up with Evotec, Apeiron
To develop immuno-oncology pills
Sanofi is teaming up with Germany's Evotec and Austrian biotech firm Apeiron Biologics to…